H2 2020 Graft Versus Host Disease (GVHD) Pipeline Review – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape. The pipeline guide provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 12, 38, 15, 3, 39, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease.
• The pipeline guide reviews pipeline therapeutics by companies and universities/research institutes based on information derived from company and industry-specific sources.

(Read more…)

• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

Key Topics Covered:

• Graft Versus Host Disease (GVHD) – Overview
• Graft Versus Host Disease (GVHD) – Therapeutics Development
• Graft Versus Host Disease (GVHD) – Therapeutics Assessment
• Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development
• Graft Versus Host Disease (GVHD) – Drug Profiles
• Graft Versus Host Disease (GVHD) – Dormant Projects
• Graft Versus Host Disease (GVHD) – Discontinued Products
• Graft Versus Host Disease (GVHD) – Product Development Milestones

Companies Mentioned

• AbbVie Inc
• Adienne Pharma & Biotech
• AltruBio Inc
• Amgen Inc
• AnaptysBio Inc
• apceth Biopharma GmbH
• ASC Therapeutics Inc
• AstraZeneca Plc
• Athersys Inc
• Autolus Therapeutics Plc
• Bellicum Pharmaceuticals Inc
• Biocon Ltd
• Biogen Inc
• BioIncept LLC
• BioTheryX Inc
• BlueRock Therapeutics
• Boryung ViGenCell Inc
• Bristol-Myers Squibb Co
• Capricor Therapeutics Inc
• Cellect Biotechnology Ltd
• Cellective BioTherapy Inc
• Cellix Bio Pvt Ltd
• CheckPoint Immunology Inc
• Clinigen Group Plc
• CSL Ltd
• CTI BioPharma Corp
• Cytodyn Inc
• Cytopeutics Pte Ltd
• Daewoong Pharmaceutical Co Ltd
• Dualogics Corp
• Educell doo
• Eli Lilly and Co
• enGene Inc
• Enlivex Therapeutics Ltd
• Evive Biotech
• ExCellThera Inc
• F. Hoffmann-La Roche Ltd
• Fate Therapeutics Inc
• Fujifilm Holdings Corp
• Genentech USA Inc
• GigaGen Inc
• GlaxoSmithKline Plc
• Glia LLC
• Humanigen Inc
• iCELL Biotechnology Co Ltd
• Immplacate
• Immune Modulation Inc
• ImmuneTarget Inc
• Imstem Biotechnology Inc
• Incyte Corp
• Inspyr Therapeutics Inc
• Jazz Pharmaceuticals Plc
• JN Biosciences LLC
• Kadmon Corp LLC
• Kalytera Therapeutics Inc
• Kamada Ltd
• Kiniksa Pharmaceuticals Ltd
• Kymab Ltd
• LG Chem Ltd
• MaaT Pharma
• Machavert Pharmaceuticals LLC
• Magenta Therapeutics Inc
• Mallinckrodt Plc
• Medexus Pharmaceuticals Inc
• Medicenna Therapeutics Corp
• Mediolanum farmaceutici SpA
• Medsenic SAS
• Mereo Biopharma Group Plc
• Mesoblast Ltd
• Millennium Pharmaceuticals Inc
• MitoImmune Therapeutics Inc
• NapaJen Pharma Inc
• Neovii Pharmaceuticals AG
• Nurix Therapeutics Inc
• OncoImmune Inc
• OSE Immunotherapeutics
• Panorama Research Inc
• Pfizer Inc
• Platinum Biotech (Beijing) Co Ltd
• Pluristem Therapeutics Inc
• Precision Biosciences Inc
• REGiMMUNE Corp
• SCM lifescience Co Ltd
• Seattle Genetics Inc
• Secura Bio Inc
• Seres Therapeutics Inc
• Shenzhen Chipscreen Biosciences Co Ltd
• STERO Biotechs Ltd
• StingInn LLC
• Suzhou Connect Biopharmaceuticals Ltd
• Suzhou Zelgen Biopharmaceutical Co Ltd
• Syndax Pharmaceuticals Inc
• Synthetic Biologics Inc
• Takeda Pharmaceutical Co Ltd
• Targazyme Inc
• TCF GmbH
• TeraImmune Inc
• TGV Laboratories Inc
• United BioPharma Inc
• Vault Pharma Inc
• Visterra Inc
• Xenikos BV
• Xenothera SAS
• XL-protein GmbH

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5773b4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900